A Phase 2 interventional study of Ruxolitinib in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-28.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing ruxolitinib in Myeloproliferative Disorders — 2 open to participants now, 4 under way, none of them phase 3. ruxolitinib · Myeloproliferative Disorders.
Among the 19 studies testing ruxolitinib in Myeloproliferative Disorders, this one is the 7th largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 2, and was the 5th registered.
668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.
Browse Myeloproliferative Disorders studies →2 of the 19 studies testing ruxolitinib in Myeloproliferative Disorders are open now, in 1 country. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+ · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 11 · Phase 3 3 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 47 across 463 interventional studies indexed under Myeloproliferative Disorders.
Median enrollment 49 across the 19 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
25 studies in Myeloproliferative Disorders by Incyte Corporation: 3 open now, 7 under way, none of them phase 3. Of 18 finished, 15 (83%) have results posted.
Among the 25 studies in Myeloproliferative Disorders by Incyte Corporation, this one is the 17th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2011, is one of 10 in phase 2, and was the 4th registered.
Incyte Corporation’s Myeloproliferative Disorders studies by the year they started, since 2008.
2 of the studies testing ruxolitinib in Myeloproliferative Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing ruxolitinib in Myeloproliferative Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Incyte Corporation’s 25 in Myeloproliferative Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10\^9/L to 100 x 10\^9/L. It is anticipated that individualized dose optimization from the starting ruxolitinib level of 5 mg bid will be associated with reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.
Drug: Ruxolitinib
Ruxolitinib (INCB018424), 5 mg bid
Also known as: INCB018424
Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose
Magnetic resonance imaging (MRI) of the upper and lower abdomen and pelvis was performed to assess spleen volumes. Computed tomography (CT) scan was performed if participant was not a candidate for MRI or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.
Time frame: Baseline and Week 24
Percent Change From Baseline in Total Symptom Score (TSS) as Measured by the Modified Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 Diary at Week 24 by Final Titrated Dose
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.
Time frame: Baseline and Week 24
Percentage of Participants With Treatment-emergent Adverse Events (TEAE)
TEAE was defined as adverse events that began or worsened from baseline after the first administration of the study drug. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.
Time frame: Up to Week 156
Percentage of Participants With New Onset Grade 4 Thrombocytopenia Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE V4.03)
Participants with platelet count between 50 and 100 × 10\^9/L at the screening and/or baseline visit were enrolled in the study. Thrombocytopenia is defined as a condition with low blood platelet count. Grade 4 thrombocytopenia was platelet count \< 25 × 10\^9/L. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.
Time frame: Up to Week 156
Percentage of Participants With New Onset Grade 2 or Higher Hemorrhage as Assessed by CTCAE V4.03
Hemorrhages were defined as any lower level terms by MedDRA included in the Standardized MedDRA Query (SMQ) for hemorrhage terms. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.
Time frame: Up to Week 156
Percent Change in Spleen Volume at Week 24 Compared to Baseline
MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant was not a candidate for MRI, or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.
Time frame: Baseline and Week 24
Percent Change in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms..
Time frame: Baseline and Week 24
Percentage of Participants With ≥ 35% Reduction in Spleen Volume at Week 24 Compared to Baseline
MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.
Time frame: Baseline and Week 24
Percentage of Participants With ≥10% Reduction in Spleen Volume at Week 24 Compared to Baseline
MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.
Time frame: Baseline and Week 24
Percentage of Participants With ≥ 50% Improvement in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.
Time frame: Baseline and Week 24
Change in Spleen Length Measured by Palpation
Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.
Time frame: Up to Week 156
Percent Change From Baseline in Spleen Length Measured by Palpation
Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.
Time frame: Up to Week 156
Patient Global Impression of Change (PGIC) Score at Each Visit
Symptoms of myelofibrosis were assessed using the PGIC questionnaire. Using the questionnaire, patients rated the overall sense of treatment effect on their symptoms on a scale of 1 (very much improved)- 7(very much worse). The specific wording was: Since the start of the treatment you've received in this study, your myelofibrosis symptoms are: 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse. A higher score indicates worse symptoms.
Time frame: Up to Week 156
Participants took part in the study at 27 investigative sites in the United States from 15 June 2011 to 19 December 2018.
| Milestone | Ruxolitinib 5 Milligram (mg) |
|---|---|
| Started | 66 |
| Completed | 42 |
| Not completed | 24 |
| Withdrew: Death | 1 |
| Withdrew: Adverse event | 3 |
| Withdrew: Consent withdrawn | 7 |
| Withdrew: Disease progression | 3 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Termination of clinical trial by sponsor | 1 |
| Withdrew: Other unspecified | 8 |
Magnetic resonance imaging (MRI) of the upper and lower abdomen and pelvis was performed to assess spleen volumes. Computed tomography (CT) scan was performed if participant was not a candidate for MRI or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.
| Percentage change from baseline | 5 mg QD or 5 mg BID | 5 mg AM/ 10 mg PM | 10 mg BID | 10 mg AM/ 15 mg PM or 15 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose | -11.6 ± 18.68 | -17.4 ± 0.63 | -22.4 ± 22.86 | -13.4 ± 22.29 |
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.
| Percentage change from baseline | 5 mg QD or 5 mg BID | 5 mg AM/ 10 mg PM | 10 mg BID | 10 mg AM/ 15 mg PM or 15 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in Total Symptom Score (TSS) as Measured by the Modified Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 Diary at Week 24 by Final Titrated Dose | -6.35 ± 64.207 | -39.51 ± NA | -47.54 ± 46.886 | 7.95 ± 113.17 |
TEAE was defined as adverse events that began or worsened from baseline after the first administration of the study drug. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.
| percentage of participants | >0 - 5 mg | >5 - 10 mg | >10 - 15 mg | >15 - 20 mg | >20 mg |
|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAE) | 93.3 | 74.2 | 61.1 | 77.3 | 55.6 |
Participants with platelet count between 50 and 100 × 10\^9/L at the screening and/or baseline visit were enrolled in the study. Thrombocytopenia is defined as a condition with low blood platelet count. Grade 4 thrombocytopenia was platelet count \< 25 × 10\^9/L. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.
| percentage of participants | >0 - 5 mg | >5 - 10 mg | >10 - 15 mg | >15 - 20 mg | >20 mg |
|---|---|---|---|---|---|
| Percentage of Participants With New Onset Grade 4 Thrombocytopenia Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE V4.03) | 23.1 | 3.0 | 5.7 | 4.7 | 0.0 |
Hemorrhages were defined as any lower level terms by MedDRA included in the Standardized MedDRA Query (SMQ) for hemorrhage terms. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.
| percentage of participants | >0 - 5 mg | >5 - 10 mg | >10 - 15 mg | >15 - 20 mg | >20 mg |
|---|---|---|---|---|---|
| Percentage of Participants With New Onset Grade 2 or Higher Hemorrhage as Assessed by CTCAE V4.03 | 6.7 | 3.0 | 1.9 | 2.3 | 11.1 |
MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant was not a candidate for MRI, or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.
| Percentage | Ruxolitinib |
|---|---|
| Percent Change in Spleen Volume at Week 24 Compared to Baseline | -17.8 ± 21.27 |
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms..
| Percentage change from baseline | Ruxolitinib |
|---|---|
| Percent Change in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline | -27.90 ± 64.818 |
MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.
| percentage of participants | 5 mg QD or 5 mg BID | 5 mg AM/ 10 mg PM | 10 mg BID | 10 mg AM/ 15 mg PM or 15 mg BID |
|---|---|---|---|---|
| Percentage of Participants With ≥ 35% Reduction in Spleen Volume at Week 24 Compared to Baseline | 4.8 (0.1 to 23.8) | 0.0 (0.0 to 70.8) | 24.2 (11.1 to 42.3) | 28.6 (3.7 to 71.0) |
MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.
| percentage of participants | 5 mg QD or 5 mg BID | 5 mg AM/ 10 mg PM | 10 mg BID | 10 mg AM/ 15 mg PM or 15 mg BID |
|---|---|---|---|---|
| Percentage of Participants With ≥10% Reduction in Spleen Volume at Week 24 Compared to Baseline | 42.9 (21.8 to 66.0) | 66.7 (9.4 to 99.2) | 63.6 (45.1 to 79.6) | 28.6 (3.7 to 71.0) |
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.
| percentage of participants | 5 mg QD or 5 mg BID | 5 mg AM/ 10 mg PM | 10 mg BID | 10 mg AM/ 15 mg PM or 15 mg BID |
|---|---|---|---|---|
| Percentage of Participants With ≥ 50% Improvement in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline | 28.6 (11.3 to 52.2) | 0.0 (0.0 to 70.8) | 44.1 (27.2 to 62.1) | 28.6 (3.7 to 71.0) |
Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.
| cm | 5 mg QD or 5 mg BID | 5 mg AM/ 10 mg PM | 10 mg BID | 10 mg AM/ 15 mg PM or 15 mg BID |
|---|---|---|---|---|
| Baseline | 11.48 ± 5.810 | 14.00 ± 4.359 | 13.13 ± 8.241 | 14.71 ± 6.726 |
| Change at Week 4 | -3.40 ± 3.068 | -4.00 ± 6.083 | -1.84 ± 3.195 | 0.00 ± 3.688 |
| Change at Week 8 | -4.65 ± 3.558 | -5.33 ± 4.933 | -2.81 ± 3.514 | -1.14 ± 2.340 |
| Change at Week 12 | -4.53 ± 4.812 | -6.50 ± 3.536 | -3.74 ± 5.118 | -3.71 ± 7.544 |
| Change at Week 16 | -3.79 ± 4.973 | -4.50 ± 3.536 | -3.69 ± 4.343 | -2.00 ± 2.449 |
| Change at Week 20 | -4.56 ± 4.844 | -7.50 ± 4.950 | -5.28 ± 5.567 | -3.50 ± 7.064 |
| Change at Week 24 | -4.25 ± 5.092 | -7.00 ± 5.657 | -4.57 ± 5.541 | -1.33 ± 3.983 |
| Change at Week 36 | -7.00 ± NA | -11.00 ± NA | -2.75 ± 3.862 | 1.00 ± NA |
| Change at Week 48 | -7.00 ± NA | -11.00 ± NA | -2.33 ± 2.517 | 0.00 ± 0.000 |
| Change at Week 60 | -7.00 ± NA | -11.00 ± NA | -2.67 ± 2.517 | 1.50 ± 2.121 |
| Change at Week 72 | -4.00 ± NA | -11.00 ± NA | -1.50 ± 2.121 | 1.00 ± NA |
| Change at Week 84 | -4.00 ± NA | — | -3.00 ± NA | -2.00 ± NA |
| Change at Week 96 | -4.00 ± NA | -8.00 ± NA | 0.00 ± NA | — |
| Change at Week 108 | -4.00 ± NA | -10.00 ± NA | 0.00 ± NA | — |
| Change at Week 120 | -4.00 ± NA | -6.00 ± NA | 2.00 ± NA | — |
| Change at Week 132 | -4.00 ± NA | -5.00 ± NA | 1.00 ± NA | — |
| Change at Week 144 | -4.00 ± NA | -3.00 ± NA | 0.00 ± NA | — |
| Change at Week 156 | -4.00 ± NA | -3.00 ± NA | 0.00 ± NA | — |
Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.
| Percentage | 5 mg QD or 5 mg BID | 5 mg AM/ 10 mg PM | 10 mg BID | 10 mg AM/ 15 mg PM or 15 mg BID |
|---|---|---|---|---|
| Percent Change at Week 4 | -38.61 ± 36.532 | -26.62 ± 36.906 | -21.88 ± 33.800 | -1.42 ± 22.902 |
| Percent Change at Week 8 | -50.64 ± 39.930 | -37.95 ± 28.772 | -28.32 ± 31.151 | -8.72 ± 13.991 |
| Percent Change at Week 12 | -49.90 ± 48.623 | -50.35 ± 8.348 | -38.21 ± 39.936 | -22.41 ± 40.833 |
| Percent Change at Week 16 | -43.24 ± 48.173 | -32.99 ± 15.222 | -38.67 ± 36.070 | -14.33 ± 14.903 |
| Percent Change at Week 20 | -44.58 ± 46.490 | -56.60 ± 17.187 | -48.06 ± 38.826 | -27.75 ± 39.024 |
| Percent Change at Week 24 | -45.39 ± 53.913 | -51.04 ± 25.043 | -42.01 ± 36.899 | -9.89 ± 25.001 |
| Percent Change at Week 36 | -58.33 ± NA | -68.75 ± NA | -20.76 ± 27.637 | 5.00 ± NA |
| Percent Change at Week 48 | -58.33 ± NA | -68.75 ± NA | -31.82 ± 19.285 | 0.00 ± NA |
| Percent Change at Week 60 | -58.33 ± NA | -68.75 ± NA | -36.36 ± 12.856 | 15.00 ± NA |
| Percent Change at Week 72 | -33.33 ± NA | -68.75 ± NA | -27.27 ± NA | 5.00 ± NA |
| Percent Change at Week 84 | -33.33 ± NA | — | -27.27 ± NA | -10.00 ± NA |
| Percent Change at Week 96 | -33.33 ± NA | -50.00 ± NA | — | — |
| Percent Change at Week 108 | -33.33 ± NA | -62.50 ± NA | — | — |
| Percent Change at Week 120 | -33.33 ± NA | -37.50 ± NA | — | — |
| Percent Change at Week 132 | -33.33 ± NA | -31.25 ± NA | — | — |
| Percent Change at Week 144 | -33.33 ± NA | -18.75 ± NA | — | — |
| Percent Change at Week 156 | -33.33 ± NA | -18.75 ± NA | — | — |
Symptoms of myelofibrosis were assessed using the PGIC questionnaire. Using the questionnaire, patients rated the overall sense of treatment effect on their symptoms on a scale of 1 (very much improved)- 7(very much worse). The specific wording was: Since the start of the treatment you've received in this study, your myelofibrosis symptoms are: 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse. A higher score indicates worse symptoms.
| score on a scale | 5 mg QD or 5 mg BID | 5 mg AM/ 10 mg PM | 10 mg BID | 10 mg AM/ 15 mg PM or 15 mg BID |
|---|---|---|---|---|
| Week 4 | 2.8 ± 0.89 | 2.8 ± 1.26 | 2.6 ± 1.09 | 3.3 ± 0.76 |
| Week 8 | 2.7 ± 1.22 | 2.3 ± 0.96 | 2.2 ± 0.99 | 2.9 ± 0.69 |
| Week 12 | 2.4 ± 0.96 | 2.3 ± 1.15 | 2.2 ± 1.17 | 3.4 ± 1.27 |
| Week 16 | 2.4 ± 0.83 | 2.0 ± 1.00 | 1.9 ± 0.91 | 3.3 ± 0.95 |
| Week 20 | 2.4 ± 0.86 | 2.3 ± 0.58 | 1.9 ± 1.11 | 2.3 ± 0.82 |
| Week 24 | 2.9 ± 1.27 | 2.3 ± 0.58 | 1.9 ± 0.98 | 2.0 ± 1.00 |
| Week 36 | 2.0 ± NA | 3.0 ± NA | 1.8 ± 0.50 | 2.5 ± 0.71 |
| Week 48 | — | 2.5 ± 0.71 | 1.3 ± 0.58 | 2.0 ± 0.00 |
| Week 60 | 2.0 ± NA | 2.5 ± 0.71 | 1.7 ± 0.58 | 3.0 ± 0.00 |
| Week 72 | 2.0 ± NA | 2.5 ± 0.71 | — | 4.0 ± NA |
| Week 84 | — | 2.0 ± NA | 1.0 ± 0.00 | 3.0 ± NA |
| Week 96 | 2.0 ± NA | 2.5 ± 0.71 | — | — |
| Week 108 | 2.0 ± NA | 2.5 ± 0.71 | 1.0 ± NA | — |
| Week 120 | 2.0 ± NA | 2.5 ± 0.71 | — | — |
| Week 132 | 2.0 ± NA | 3.0 ± 1.41 | 1.0 ± NA | — |
| Week 144 | 2.0 ± NA | 2.5 ± 0.71 | 1.0 ± NA | — |
| Week 156 | 2.0 ± NA | 3.0 ± 1.41 | 1.0 ± NA | — |
Collected over Up to approximately 161 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| >0 - 5 mg | 0/15 (0%) | 5/15 (33.3%) | 13/15 (86.7%) |
| >5 - 10 mg | 0/66 (0%) | 8/66 (12.1%) | 43/66 (65.2%) |
| >10 - 15 mg | 0/54 (0%) | 4/54 (7.4%) | 26/54 (48.1%) |
| >15 - 20 mg | 2/44 (4.5%) | 9/44 (20.5%) | 31/44 (70.5%) |
| >20 mg | 0/9 (0%) | 1/9 (11.1%) | 5/9 (55.6%) |
| Event | >0 - 5 mg | >5 - 10 mg | >10 - 15 mg | >15 - 20 mg | >20 mg |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/15 | 1/66 | 0/54 | 1/44 | 1/9 |
| LeukocytosisBlood and lymphatic system disorders | 1/15 | 0/66 | 0/54 | 0/44 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/15 | 0/66 | 0/54 | 0/44 | 0/9 |
| Atrial fibrillationCardiac disorders | 1/15 | 0/66 | 0/54 | 0/44 | 0/9 |
| Cardiac failure congestiveCardiac disorders | 1/15 | 0/66 | 0/54 | 0/44 | 0/9 |
| Abdominal painGastrointestinal disorders | 1/15 | 0/66 | 1/54 | 1/44 | 0/9 |
| NauseaGastrointestinal disorders | 1/15 | 0/66 | 0/54 | 0/44 | 0/9 |
| VomitingGastrointestinal disorders | 1/15 | 0/66 | 0/54 | 0/44 | 0/9 |
| DizzinessNervous system disorders | 1/15 | 1/66 | 0/54 | 0/44 | 0/9 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/15 | 0/66 | 0/54 | 0/44 | 0/9 |
| Event | >0 - 5 mg | >5 - 10 mg | >10 - 15 mg | >15 - 20 mg | >20 mg |
|---|---|---|---|---|---|
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 0/15 | 1/66 | 0/54 | 0/44 | 2/9 |
| Night sweatsSkin and subcutaneous tissue disorders | 0/15 | 4/66 | 0/54 | 2/44 | 2/9 |
| AnaemiaBlood and lymphatic system disorders | 3/15 | 7/66 | 4/54 | 5/44 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/15 | 11/66 | 4/54 | 2/44 | 1/9 |
| Oedema peripheralGeneral disorders | 1/15 | 9/66 | 4/54 | 6/44 | 0/9 |
| Upper respiratory tract infectionInfections and infestations | 1/15 | 3/66 | 2/54 | 6/44 | 1/9 |
| Abdominal painGastrointestinal disorders | 2/15 | 4/66 | 2/54 | 2/44 | 1/9 |
| NauseaGastrointestinal disorders | 2/15 | 6/66 | 2/54 | 4/44 | 0/9 |
| VomitingGastrointestinal disorders | 2/15 | 3/66 | 0/54 | 3/44 | 0/9 |
| FatigueGeneral disorders | 2/15 | 7/66 | 5/54 | 3/44 | 1/9 |
Safety evaluable population included participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Ruxolitinib 5 mg |
|---|---|
| Mean | 68.7 ± 9.44 |
| Sex: Female, Male(Participants) | Ruxolitinib 5 mg |
|---|---|
| Female | 27 |
| Male | 39 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib 5 mg |
|---|---|
| Ethnicity — Hispanic or Latino | 3 |
| Ethnicity — Non-Hispanic or Non-Latino | 63 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib 5 mg |
|---|---|
| Race — White | 58 |
| Race — Black or African American | 4 |
| Race — Asian | 2 |
| Race — Native Hawaiian or Pacific Islander | 1 |
| Race — Other | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2011 to primary completion in Dec 2018, 90 months.
Results were first posted in Jan 2020, 1 year 1 month after primary completion.
Of 87 phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 111. This study's 90 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib
Myeloproliferative Disorders →